Fecal marker levels as predictors of need for endoscopic balloon dilation in Crohn’s disease patients with anastomotic strictures

Table 1 Patient characteristics, n = 48

Characterization	n (%)
Women,	22 (45.8)
Median time between diagnosis and surgery, mo (IQR)	36.0 (14.0-120.0)
Median time between surgery and endoscopic evaluation, mo (IQR)	114.5 (60.8-199.0)
Median age at endoscopic evaluation, yr (IQR)	46.5 (39.3-53.4)
Montreal classification
Age at diagnosis
A1, ≤ 16 yr	6 (12.5)
A2, 17-40 yr	33 (68.8)
A3, > 40 yr	9 (18.8)
Location
L1: ileal	30 (62.5)
L3: ileocolonic	17 (35.4)
L4: upper gastrointestinal tract	1 (2.1)
Behavior
B1: non-stricturing, non-penetrating	1 (2.1)
B2: stricturing	27 (56.2)
B3: penetrating	20 (41.7)
Perianal disease	14 (29.2)
Smoking
Never	26 (54.2)
Current	12 (25.0)
Past	10 (20.8)
Concomitant treatment
Corticosteroids	9 (18.8)
Immunomodulators (Azathioprine/6MP/ Methotrexate)	26 (54.2)
Biologics (Infliximab, adalimumab)	20 (41.7)
5-ASA	17 (35.4)
Median fecal calprotectin, μg/g (IQR)	134.0 (35.3-321.0)
Median, fecal lactoferrin, μg/g (IQR)	6.2 (2.0-22.4)
Modified Rutgeerts score
i0, i1, i2a	26 (54.2)
i2b, i3, i4	22 (45.8)
Subocclusive symptoms	8 (16.7)
Harvey-Bradshaw index
Remission (HBI < 5)	40 (83.3)
Mild disease (HBI 5-7)	8 (16.7)
Need of redilation	14 (29.2)
Surgery after dilation	2 (1.4)
Median follow up, mo (IQR)	34.0 (27.5-52.5)

HBI: Harvey-Bradshaw index; IQR: Interquartile range.